Abstract
Background A novel coronavirus (SARS-CoV-2) spread from the capital of the Hubei province in China to the rest of the country, then to most of the world. To anticipate future trends in the development of the epidemic, we explore here, based on public records of infected persons how variation in the virus tropism could end up in different patterns, warranting specific way to handle the epidemic.
Methods We use a compartmental model to describe the evolution of an individual through several possible states: susceptible, infected, alternative infection, detected and removed. We fit the parameters of the model to the existing data taking into account significant quarantine changes where necessary.
Results The model indicates that Wuhan quarantine measures were effective but that alternative virus forms and a second propagation route are compatible with available data. For Singapore and Shenzhen region the secondary route does not seem to be active yet and the epidemic size limited.
Conclusions The alternative infection tropism (the gut tropism) and a secondary propagation route are validated hypotheses using a model fitted by the available data. Corresponding prevention measures that take into account both routes should be implemented to the benefit of epidemic control.
Competing Interest Statement
AD is employed by Stellate Therapeutics (fka Amabiotics), a company that works on treatment of neurodegenerative diseases.
Funding Statement
Authors were funded by their respective employers.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
no personal of private data were used in this work.
